1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Chronic Disease Analysis & Statistics 2021 - Europe

Chronic Disease Analysis & Statistics 2021 - Europe

Customer Support

Talk to Ahmad

+1 718 618 4302

Publication dates

Publishers

  • All
    • Pharma Intelligence
1-16 of 16 reports

Drug Delivery: Inhalation Devices

  • $ 4750
  • October 2019
  • 47 pages

Overview In 2018, combined sales of inhaled asthma and COPD devices in the countries covered by this analysis totaled approximately $10.4bn. Over the forecast period covered by this analysis, total sales ...

  • World
  • Spain
  • Asthma
  • Drug Delivery
  • Industry analysis
  • Asthma Prevalence

Market Spotlight: Systemic Lupus Erythematosus (SLE)

  • $ 1318
  • May 2021
  • 40 pages

This Market Spotlight report covers the Systemic Lupus Erythematosus (SLE) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory ...

  • World
  • Europe
  • Clinical Trial
  • Musculoskeletal Disorder
  • Industry analysis
  • Drug Approval

Market Spotlight: Fibromyalgia

  • $ 1318
  • March 2021
  • 37 pages

This Market Spotlight report covers the Fibromyalgia market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability ...

  • World
  • Europe
  • Chronic Pain
  • Clinical Trial
  • Industry analysis
  • Drug Approval

Anemia in Chronic Kidney Disease KOL Interview – US, East Coast

  • $ 599
  • June 2020
  • 16 pages

This interview with a UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for renal cell carcinoma. Disease stratifications ...

  • United Kingdom
  • United States
  • Renal Cancer
  • Chronic Disease
  • Industry analysis

Type 1 Diabetes KOL Interview – UK

  • $ 599
  • January 2020
  • 13 pages

This interview with a UK Key Opinion Leader (KOL) provides insight into current therapies for type 1 diabetes, as well as pricing pressures within the diabetes market, the unmet needs in type 1 diabetes, ...

  • United Kingdom
  • Type 1 Diabetes
  • Industry analysis

Rheumatoid Arthritis Payer Interview – UK

  • $ 599
  • August 2019
  • 18 pages

Overview A UK payer provides insights into pricing and reimbursement dynamics and issues surrounding biosimilars, key marketed brands, and late-phase pipeline therapies for rheumatoid arthritis.

  • United Kingdom
  • Arthritis
  • Industry analysis

Rheumatoid Arthritis KOL Interview – UK

  • $ 599
  • July 2019
  • 14 pages

A UK-based key opinion leader provides insights into prescribing habits, the most pressing unmet needs in the market, the role of biosimilars, key marketed brands, and late-phase pipeline therapies fo ...

  • United Kingdom
  • Arthritis
  • Industry analysis

Datamonitor Healthcare Chronic Heart Failure KOL Interview – Germany

  • $ 599
  • February 2019
  • 10 pages

Overview A German KOL discusses current marketed therapies and SGLT-2 inhibitors for chronic heart failure, as well as key unmet needs in this therapeutic area.

  • Germany
  • Cardiovascular Disease
  • Sodium-Glucose Co-Transporter 2 Inhibitor
  • Industry analysis

Datamonitor Healthcare Chronic Heart Failure KOL Interview – UK

  • $ 599
  • February 2019
  • 12 pages

Overview A UK KOL provides insight into marketed and pipeline therapies for chronic heart failure, as well as key unmet needs in this therapeutic area. Key marketed drugs are highlighted, including Corlano ...

  • United Kingdom
  • Cardiovascular Disease
  • Sodium-Glucose Co-Transporter 2 Inhibitor
  • Industry analysis

Finerenone

  • $ 10000
  • February 2019
  • 19 pages

Drug Overview Finerenone (Bayer) is a third-generation potent and selective oral, non-steroidal mineralocorticoid receptor antagonist (MRA). It blocks the detrimental effects due to over-activation of ...

  • Europe
  • Japan
  • Heart Failure
  • Hormone
  • Industry analysis

Chronic Obstructive Pulmonary Disease Forecast and Market Analysis to 2026

  • $ 22000
  • April 2021
  • 64 pages

Disease Overview Chronic obstructive pulmonary disease (COPD) is defined by persistent airflow limitation (reduction in the ability to exhale at a normal rate and volume). While chronic and progressive ...

  • United States
  • World
  • Respiratory Disease
  • Industry analysis
  • Smoking Prevalence

Disease Analysis: Asthma

  • $ 22000
  • February 2021
  • 83 pages

Defintion Asthma is a chronic respiratory condition characterized by recurrent wheezing, coughing, and breathlessness, which occur in acute events known as exacerbations. Often triggered by factors such ...

  • World
  • Europe
  • Asthma
  • Industry analysis
  • Drug Approval
  • Asthma Prevalence

Disease Analysis: Asthma - Forecast and Market Analysis

  • $ 22000
  • December 2020
  • 81 pages

Defintion Asthma is a chronic respiratory condition characterized by recurrent wheezing, coughing, and breathlessness, which occur in acute events known as exacerbations. Often triggered by factors such ...

  • World
  • Europe
  • Asthma
  • Industry analysis
  • Asthma Prevalence
  • Drug Approval

Disease Analysis: Asthma - Forecast and Market Analysis to 2027

  • $ 22000
  • April 2020
  • 80 pages

Latest key takeaways The analyst estimates that in 2018, there were approximately 343.6 million prevalent cases of asthma in individuals aged up to 44 years worldwide, and forecasts that number to increase ...

  • World
  • Europe
  • Asthma
  • Industry analysis
  • Drug Approval
  • Asthma Prevalence

Diabetic Nephropathy Market and Forecast Analysis to 2026

  • $ 22000
  • February 2019
  • 236 pages

DISEASE OVERVIEW Diabetic nephropathy, also known as diabetic kidney disease, is caused by damage to small blood vessels which can cause the kidneys to be less efficient in their blood filtration role ...

  • Japan
  • United States
  • Renal Disease
  • Sodium-Glucose Co-Transporter 2 Inhibitor
  • Industry analysis

Ischemic Stroke Market and Forecast Analysis 2024

  • $ 22000
  • January 2019
  • 163 pages

Disease Overview Stroke is the second most common cause of death and a major cause of disability worldwide. A stroke occurs when there is a blockage or bleed in the cerebrovascular system that leads to ...

  • World
  • Japan
  • Stroke
  • Industry analysis


About 1900 reports

Download Unlimited Documents from Trusted Public Sources

View report >

Respiratory Disease Demographic Impact in Wales (UK)

  • October 2021
  • 9 pages
  • Wales
  • Influenza
  • Respiratory Disease
  • Industry analysis
  • Vaccination Coverage
  • Influenza Prevalence

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on